PFE250110C36000
- 0.02
- 0.000.00%
Pfizer Newsroom
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Pfizer Is Maintained at Neutral by UBS
Pfizer Analyst Ratings
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
Express News | The USA Food and Drug Administration (FDA): GlaxoSmithKline and Pfizer must issue warnings regarding their respiratory syncytial virus (RSV) vaccines. The RSV vaccines from these two companies may increase the risk of rare neurological side effects.
Pfizer Options Spot-On: On January 7th, 183.88K Contracts Were Traded, With 3.21 Million Open Interest
On January 7th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 183.88K options for the day, of which put options accounted for 38.54% of the total transactions, and
FDA Requires GSK and Pfizer Vaccines to Carry Rare Side Effect Warnings
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Express News | Market News: Pfizer executives plan to hold a meeting at Trump's Mar-a-Lago.
Express News | Pfizer Executives Descend on Donald Trump’s Mar-a-Lago for Planning Meeting - FT
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
PostEra Kündigt Ausweitung Der Zusammenarbeit Mit Pfizer Bei Der KI-Wirkstoffforschung Auf 610 Millionen US-Dollar an
PostEra Annonce L'extension À 610 Millions USD De Sa Collaboration Avec Pfizer Dans La Découverte De Médicaments Optimisée Par L'IA
U.S. pharmaceutical stocks generally rose, with Pfizer up 1.6%.
Gelonghui, January 7th | Moderna rose by 7.5%, NOVAVAX rose by 12.4%, Pfizer rose by 1.6%, and CureVac listed in the USA saw a price increase of 10.6%.